SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of ERBA Diagnostics, Inc. – ERB

NEW YORK, NY / ACCESSWIRE / November 24, 2015 / Pomerantz LLP is investigating claims on behalf of investors of ERBA Diagnostics, Inc. (“ERBA” or the “Company”) (NYSE: ERB). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether ERAB and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On November 20, 2015, ERBA disclosed that the Company’s previously issued financial statements for each of the years ended December 31, 2014 and 2013 and for each of the interim periods ended March 31, 2015 and June 30, 2015 (collectively, the “Non-Reliance Periods”) should no longer be relied upon. ERBA further disclosed that the Company intends to restate its financial statements for the Non-Reliance Periods.

On this news, shares of ERBA fell $0.30, or over 17%, to close at $1.44 on November 23, 2015.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Florida, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP

ReleaseID: 434033